clinical trial · NCT07225686
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
ObesityObstructive Sleep ApneaMaridebart cafraglutidePlacebo
brief summary
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
started
Dec 19, 2025
primary completion
Sep 29, 2027
completion
Sep 13, 2028
last updated
Aug 4, 2026
official title
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol